Kevin DeGeeter

Ladenburg Thalmann

Image: Kevin DeGeeter

Kevin DeGeeter is a director at Ladenburg Thalmann & Co. Inc. He is responsible for equity research coverage of personalized medicine and medical device companies with market capitalizations between $50 million and $2 billion. His coverage focuses on molecular diagnostics and medical equipment used in oncology, cardiovascular disease and infectious disease, as well as related research markets. Prior to joining Ladenburg Thalmann he was an analyst at Oppenheimer & Co., with responsibility for small-cap molecular diagnostic and biotechnology stocks. He has 10 years of buyside and sellside research experience, including positions with J. P. Morgan, PaineWebber, Natexis Bleichroeder and Manning & Napier Advisors. DeGeeter received a bachelor's degree in economics from Colgate University.

Recent Quotes

"MESO is now well positioned to potentially conclude partnering discussions for MPC-06-ID in the coming months; we reiterate our Buy rating."

— Kevin DeGeeter, Ladenburg Thalmann (5/10/16)
more >



Due to permission requirements, not all quotes are shown.